Search
Ivosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigational[L46287] It was fully approved by the EMA in May 2023.[L46596] … [A248745] Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults.
Donanemab
go.drugbank.com/drugs/DB16647ApprovedInvestigational[A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.
Protirelin
go.drugbank.com/drugs/DB09421ApprovedIt is a tri-peptide tropic hormone, released by the hypothalamus, that stimulates the release of Thyroid Stimulating Hormone (TSH) and prolactin from the anterior pituitary.
ISS-1018
go.drugbank.com/drugs/DB05463Investigational(TNF-alpha) by plasmacytoid dendritic cells (pDC). … ISS 1018 signals through Toll-like receptor 9 (TLR9) to induce the production of immunoglobulin by B cells and interferon (IFN) -alpha, IFN-beta, interleukin-12 (IL-12), and tumor necrosis factor - alpha
Verpasep caltespen
go.drugbank.com/drugs/DB04959InvestigationalIt is being developed by StressGen Biotechnologies Corp. … E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes.
Sirna-027
go.drugbank.com/drugs/DB05896InvestigationalSirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular degeneration.
Osemozotan
go.drugbank.com/drugs/DB05339ExperimentalMN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)
KC706
go.drugbank.com/drugs/DB05157InvestigationalKC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase.
Profenamine
go.drugbank.com/drugs/DB00392ApprovedProfenamine (also known as ethopropazine) is a medication derived from phenothiazine. It is primarily used as an antidyskinetic to treat Parkinsonism. It is sold under the trade name Parsitan in Canada. In the US, the marketing of profen...
Givosiran
go.drugbank.com/drugs/DB15066Approved[L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder